BI3034701 formulation B
DrugBI3034701 formulation B (reference treatment)
NCT Number: NCT07837648
The aim of the trial is to investigate relative bioavailability of BI 3034701 treatment T vs. BI 3034701 treatment R.
Trial opening soon.
Get Notified18 year–55 year
All sexes
Interventional
Phase 1
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
BI3034701 formulation B (reference treatment)
BI3034701 formulation C1 (test treatment)
Time frame: Up to 19 days.
Time frame: Up to 19 days.
Highest observed plasma concentrations within the time interval.
Time frame: Up to 19 days.
Contact information is provided by the study sponsor or research team.
Boehringer Ingelheim
Industry
Relative Bioavailability of Two Different BI 3034701 Treatments Following Subcutaneous Administration in Healthy Male and Female Participants (an Open-label, Randomised, Single-dose, Two-period, Two-sequence, Crossover Trial)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06120244
Healthy
Hamilton, Montana, United States
View Trial DetailsNCT07833865
Autoimmune Diseases, Diabetes Mellitus
View Trial DetailsNCT07830862
Healthy
Guelph, Ontario, Canada
View Trial DetailsNCT07823764
Healthy
Hangzhou, Zhejiang, China
View Trial Details